The long-living sharks aren't as blind as once thought and have DNA repair mechanisms that may help prevent their vision from ...
FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.
Just a few years ago, the lion’s share of investment in new ophthalmic drugs was for topical antibiotics.The target market ...
Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...
Ocugen also reported updated results from a phase 1 trial, which showed that ellipsoid zone (EZ) loss – which results in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback